Make 2x the Impact Now to Help End Alzheimer's
Make 2x the Impact Now to Help End Alzheimer's
Our March 2x Match Challenge is underway, but not for long. From now until midnight March 10, your gift can have double the impact on advancing research, and helping to provide care and support for those impacted by Alzheimer’s.
Donate NowAlzheimer's Association Statement on FDA Decision to Hold Advisory Committee Meeting to Discuss Donanemab
CHICAGO, March 8, 2024 — The Alzheimer's Association appreciates the Food and Drug Administration's (FDA) thorough process in reviewing treatments for Alzheimer's disease. The FDA has determined it will hold an advisory committee meeting on donanemab (Lilly). While the decision is a surprise at this stage in the review process, the safety and appropriate administration of treatments is paramount.
On behalf of everyone who could benefit from this treatment, we strongly urge the FDA to move swiftly in this next stage of its review.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
The first survivor of Alzheimer's is out there, but we won't get there without you.
Donate Now
Learn how Alzheimer’s disease affects the brain.
Take the Brain Tour